Clinuvel Pharmaceuticals Ltd has released a press release.
FDA awards SCENESSE Fast Track designation for EPP treatment
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- SCENESSE launched in Europe
- SCENESSE Treatment in Europe
- SCENESSE attains breakthrough European Market Authorisation
- US patent for alpha-MSH and analogues
- Patent to assist drug as potential skin cancer preventative
Later from Clinuvel Pharmaceuticals
- FDA accept SCENESSE clinical data package for NDA submission
- Clinuvel completes combination therapy pre-clinical study
- FDA Schedules Pre-NDA Meeting for SCENESSE
- SCENESSE - NICE England Update
- CLINUVEL agrees with FDA on New Drug Application timelines
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals